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In cardiology, functional platelet activity is not routinely monitored. Platelet function
assays should be able to identify patients with high residual platelet reactivity (HPR). High
on-treatment platelet reactivity is apparent risk factor for atherothrombosis, however not
the only one. Since there are many contributing factors (platelet activation, endothelial
dysfunction, and plaque rupture) influencing atherothrombosis. Antiplatelet treatment is
targeted to diminish platelet activation. The unique pharmacodynamics, pharmacoki-
netics of each agent and the pharmacogenetic profile of the recipient need to be taken into
consideration. The aim of this review article is to summarize current knowledge of platelet
function monitoring and its usefulness in clinical cardiology.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Aspirin (ASA) and thienopyridines are the cornerstone of anti-
platelet treatment in patients after vascular intervention with
stenting. ASA can prevent up to 20–25% of ischemic vascular
events (myocardial infarction and cerebrovascular events)
according to the multicenter trial, Antithrombotic Trialist Colla-
boration [1]. The thienopyridine, clopidogrel reduces the relative
risk of ischemic vascular complications by only 8.7% in compar-
ison with ASA [2]. To account for failure, the notion of antiplate-
let treatment resistance has evolved but to date there is no exact
definition of aspirin/clopidogrel resistance. Aspirin/clopidogrel
resistance represents inadequate cyclooxygenase-1/ADP block-
ade in the face of sufficient bioavailability. The final cascade
effects are difficult to measure and thus indirect evaluation at
platelet blockade level has to suffice. Clinical resistance refers to
the inability to prevent ischemic vascular events. On the other
hand, biochemical resistance is demonstrated by platelet func-
tion test abnormalities which are dependent on aggregation
agonists, type of assay used and a number of other factors.
Hankey et al. [3] describe resistance as ‘‘insufficient response
to standard dose of aspirin in compliant patient identified by
reliable, consistent and independent platelet function assay,
which correlates strongly with ischemic vascular events.’’
Treatment non-compliance, which can lead to ‘‘pseudore-
sistance’’, is difficult to confirm and is often overlooked by
researchers and clinicians. To capture poor antiplatelet treat-
ment response, lately the term ‘‘high on-treatment platelet
reactivity’’ is used instead.2. The role of platelets in arterial thrombosis
Arterial thrombosis is a complex process activated by vessel
intima rupture mostly due to progressive atherosclerosis.
Subendothelial structures like von Willebrandt factor and
collagen are exposed to the blood stream and this results in
binding with platelet glycoproteins Ib/V/IX, Ia/IIa [4]. This
cascade leads to platelet activation. Development of platelet
activation can be described in three crucial steps: (a) con-
formational change of glycoprotein IIb/IIIa increasing its
binding affinity, (b) release of platelet activation agonist as
ADP or thromboxane A2(TxA2) into the bloodstream where it
binds to platelets and (c) conformational/shape change.
TxA2 is a key element in the formation of primary hemo-
static clot and acceleration of platelet activation.
TxA2 causes (1) increased fibrinogen receptor expression,
(2) vasoconstriction and (3) by positive feedback, increased
production of its precursor, arachidonic acid [5]. Activated
platelets due to their intra- and intercellular signalization are
essential in the process of primary hemostasis and subse-
quent coagulum formation. For these reasons, treatment of
both acute cardiovascular events, primary and secondary
prevention aims to block platelets in different ways.3. Aspirin and the other guys
Acetylsalicylic acid (ASA) was one of the first synthesized
drugs. It is still being investigated for its preventive role in e.g.colorectal cancer [6]. By blocking directly and irreversibly,
cyclooxygenase-1(COX-1), ASA prevents the formation of the
unstable product prostaglandin H2, from which would other-
wise originate TxA2 via thromboxansynthase. Since platelets
have minimal protheosynthetic equipment and no nucleus,
the resynthesis of COX-1 is impossible. The effect of ASA
lasts from 7 to 10 days. Roughly 10% of the total platelet pool
is daily substituted and in stress reactions such as surgery or
systemic inflammatory activity even more [7]. In primary
prevention, ASA is capable of preventing 20–25% undesirable
ischemic vascular events, in secondary prevention by opti-
mistic assumptions up to 40% [8]. ASA has no effect on
mortality and there are gender differences. It lowers the
incidence of myocardial infarction in males and cerebrovas-
cular events in females [1]. In the majority of patients, low
dose ASA (75–100 mg/daily) results in 95% blockade of COX-1
[9], and the effect is cumulative. While COX-1 is produced
constitutively, the formation of COX-2 is increased up to 20
in inflammatory disease, including the sterile inflammation
of atherosclerosis [10].
Nucleus containing cells such as macrophages andmonocytes
can contribute to COX-1 independently of TxA2 production and
can supercede the effects of ASA.
The population variability in ASA responsivness is geneti-
cally determined as 1–13%, mostly due to COX-1 independent
chronically increased platelet activity/aggregability [11].
Clopidogrel belongs to the thienopyridine drug group whose
primary therapeutic target is non-competitive irreversible
ADP receptor (P2Y12) blockade. P2Y12 receptor signalization
is necessary for integrin IIb/IIIa full activation [4], which is a
key factor in platelet irreversible aggregation.
In this review, we discuss mostly clopidogrel because of its
superiority over ticlopidin and lack of data for prasugrel func-
tion monitoring. Clopidogrel is 6 stronger P2Y12 blocker than
ticlopidin. It reaches faster effective plasma levels and has
fewer major side effects such as neutropenia and thrombotic
thrombocytopenic purpura [12]. Both clopidogrel and ticlopidin
are prodrugs which is their greatest shortcoming. The bioavail-
ability depends both on gastrointestinal absorption and cyto-
chrome P450 metabolism. Up to 85% of absorbed drug is
converted into ineffective metabolite. Another 15% of the final
agent R-130964 is covalently bound to the P2Y12 receptor
which is still sufficient to provide irreversible ADP-dependent
platelet blockade [4]. In the CAPRIE trial, clopidogrel 75mg/daily
reduced the relative risk of ischemic events and cardiovascular
death by 8.7% points in comparison with 375mg of ASA [13].
Thienopyridines and clopidogrel in particular, are the
cornerstone of treatment/prevention of ischemic vascular
events after percutaneous coronary interventions with stent
implantation as demonstrated in the CLASSICS trial [14].
Glycoprotein IIb/IIIa blockers are discussed according to
treatment failure/HPR to a lesser extent
There are three subgroups of these: monoclonal antibodies to
IIb/IIIa, peptides and peptidomimetics. For sufficient platelet
blockade, 80% receptor saturation is needed [14]. The first
clinical results of these drugs were very disappointing, however.
No short term mortality reduction was found in patients after
percutaneous coronary interventions(PCI) although long-term
cardiovascular mortality reduction after initial IIb/IIIa antago-
nist administration during PCI was demonstrated [15].
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 0 5 – e 3 1 3 e3073.1. Aspirin resistance
The concept of aspirin treatment failure stemmed from the
naive idea, that antiplatelet treatment would prevent all
ischemic vascular events. Given the nature of atherosclerotic
lesions, it is not possible to prevent all episodes with ASA.
ASA, as described earlier, affects COX-1 dependent produc-
tion of thrombogenic and vasoconstricitve TxA2. The block-
ade of one particular path of platelet activation will not
prevent the formation of primary hemostatic clot in the case
of ruptured atherosclerotic lesion and uncovered suben-
dothelial structures. On the other hand, it would not be
desirable to compromise the primary hemostasis completely,
owing to increased risk of bleeding. We mention by the way,
that patients with Glanzmann thrombastenia have an extre-
mely low incidence of myocardial infarction and cerebrovas-
cular accidents. In primary prevention, ASA in standard dose
(75–325 mg/daily) is able to prevent almost 20% of ischemic
vascular events. The question is, what part of the remaining
80% is caused by HPR. True biochemical resistance refers to
ineffective COX-1 blockade in cases of adequate bioavailabil-
ity. Standard ASA dosing of 75–325 mg is enough to exhibit
95% COX-1 inhibition [9]. For this reason, insufficient ASA
dosing should not play a role in HPR. Some patients are able
to produce platelet-independent TxA2. This may be caused by
activation of the monocyte–macrophage system and endothelial
COX-2, which is not blocked by ASA [16]. In smokers, COX-2
activity is increased and this is one reason for the high
cardiovascular risk in smokers [17], and may be linked to
aspirin treatment failure.
On the other hand ‘‘smokers paradox’’ is widely known:
tobacco smoking increases the clopidogrel antiplatelet effect.
Stress reactions (surgery, inflammation and pain) may elevate
the population of COX-1 ‘‘uninhibited’’ platelet by increasing
platelet turnover. This may contribute to ‘‘treatment failure’’,
while the ASA biological half-life is only 20 mins [18]. The
Framingham study data demonstrated genetic factors to
be responsible for at least 1/3 of the variability of response
to ASA [19]. Modified ASA response may be caused by
single nucleotide polymorphism of COX-1/COX-2 genes or
platelet glycoprotein receptors [20]. Decreased bioavailability
of ASA may be due to impaired absorption from intestine or
increased/accelerated metabolism. The reasons for decreased
bioavailability could more simply, non-compliance which
should be taken into consideration especially in geriatric
populations. For example, one trial on acute myocardial infarc-
tion patients, showed an alarming 40% of probands not taking
ASA [21]. Another reason for ASA ‘‘treatment failure’’ may be
COX-1 receptor competition. This situation arises in the case of
concomitant treatment with ASA and NSAIDS. At least for
ibuprofen and naproxen there are data confirming decreased
ASA efficacy using the measure thromboxane B2 in urine and
platelet function assays [22,23]. There is a broad range of causes
for ASA treatment failure/HPR. The major question remains,
valid and standard tests for this. The prevalence of ASA HPR
ranges from 5 to 40% and depends greatly on the platelet
function assay used [24]. Urine thromboxane B2 (TxB2) was
shown to be a promising test of ASA treatment effect in the
Canadian HOPE trial participants [25]. The relation between
cardiovascular ischemic vascular events incidence and urineTxB2 was examined. According to the HOPE trial ‘‘ASA resis-
tance’’ is more continuous than categorical. There is moderate
correlation between HPR and urine TxB2. The pitfalls are
interference by renal insufficiency and absence of ‘‘cut-off’’
value for HPR. Nevertheless, urine TxB2 together with light
thrombocyte aggregometry are used as gold standards for
comparison with other platelet function assays.
3.2. Clopidogrel resistance
Clopidogrel has demonstrated efficacy in atherothrombosis
prevention in a number of trials and has been used in common
clinical practice for some time. There is ample literature on
clopidogrel response variability in different patient populations.
Like ASA, clopidogrel HPR is multifactorial. Clopidogrel HPR/
inadequate response is estimated to be from 5 to 40% [26].
Genetic factors play a more important role in clopidogrel than
in ASA. Clopidogrel is a pro-drug and 2-step liver metabolism
depends on cytochrome P450 gene polymorphism. CYP2C192
variant carriers were determined to have 6 increased risk of
atherothrombotic stent closure. The population incidence of
this allele is estimated to be 30% [27]. However, positive
predictive value of CYP2C19 loss-of function polymorphism
for undesirable cardiovascular events (stent thrombosis etc.) is
low (12–20%) [28]. In the ELEVATE-TIMI 56 trial it was shown
that tripling the clopidogrel to 225mg led to comparable
platelet blockade in CYP2C192 heterozygotes as in non-
carriers. Homozygotes for CYP2C192 did not achieve sufficient
platelet blockade even after 300mg of clopidogrel [29]. In a
controversial meta analysis of 42,016 patients no increased risk
for cardiovascular events in CYP2C192 carriers was identified
[30] but not only CYP2C192 homozygotes were included.
Genetic polymorphisms of cytochrome P450 are not the only
cause of higher platelet reactivity followed by treatment failure.
As in any other drug, in some patients, the absorption of
clopidogrel can be impaired or slower. Alternatively, there
may be a cytochrome P450 CYP3A4 receptor induction by some
other drug or food (herbal tea, grapefruit juice etc.), increasing
clopidogrel metabolism. In the literature, most often mentioned
are statins and proton pump blocker concomitant treatment
proved not to have increased risk of cardiovascular ischemic
events [31–33]. Although one study demonstrated decrease in
P2Y12 clopidogrel inhibitory effect after omeprazol administra-
tion by vasodilator stimulated phosphoprotein, no expected
increase in incidence of cardiovascular end-points was found
[34]. In contrast, there were ‘‘pre-defined’’ patient groups with
acute coronary syndrome with increased initial high platelet
reactivity/platelet activation, linked to adverse cardiovascular
events (periprocedural myocardial infarction, stent thrombosis)
[35]. This group consisted mostly of patients with diabetes
mellitus, obesity and manifest metabolic syndrome.
3.3. IIb/IIIa blocker resistance?
Strictly we can question all these causes of resistance as they
do not fulfill the pathophysiological basis of resistance.
Moreover it evokes the categorical rather than the true
continuous nature of this phenomenon. In the case of IIb/
IIIa blockers it is virtually meaningless. We should be con-
sidering the level of blockade/residual platelet reactivity
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and to the doseþlength of infusion in the case of parenteral
administration. The first trials in IIb/IIIa blockers were dis-
appointing. Later on, the partial receptor agonism, mild pro
inflammatory activation and narrow therapeutic range were
discovered to explain the primary failure [4]. In the following
trials, where narrow therapeutic range was taken into con-
sideration, the safety and efficacy in high risk PCI, especially
with native vessel or stent thrombosis, was demonstrated
[36]. There is a dearth of current data describing treatment
failure to glycoprotein IIb/IIIa blockers using platelet function
assays. Increased antiplatelet effect after high-dose tirofiban
in comparison with standard dose of abciximab have been
described [37]. Selective ‘‘downstream’’ administration of gp
IIb/IIIa inhibitors following 600 mg clopidogrel LD was shown
to be effective in non-ST elevation troponin-positive acute
coronary syndrome [38]. Moreover gp IIb/IIIa blockers were
demonstrated to be highly effective in reducing both peripro-
cedural and long-term ischemic outcomes when given to
patients with HPR [39,40]. Interindividual response variability
to gp IIb/IIIa cannot be determined as ‘‘easily’’ as in case of
ASA/clopidogrel. In the clinical settings it is complicated to
monitor gp IIb/IIIa blockade specifically since other antiplate-
let drugs are being administered at the same time.
3.4. Platelet function assays
Platelet function assays aim to assess the level of response to
antiplatelet drugs in patients with ischemic cardiovascular
diseases. In primary prevention it would be seminal to
identify patients with high risk of first atherothrombotic
episode. In secondary prevention it would be reasonable to
diminish the risk of stent thrombosis by platelet function
assay tailored treatment. Platelet function assays may be
arbitrarily divided into laboratory and point-of care (POCT)
tests. There is a broad spectrum of both (Table 1). The gold
standard of platelet function monitoring is classical light
transmittance aggregometry (LTA), in part due to its histor-
ical first application. LTA is a full laboratory method, both
technically and time demanding. The method is based on the
measurement of light transmittance through a platelet-rich
plasma sample. The transmittance is increased by subse-
quent platelet aggregation caused by addition of the
aggregation agonist (ADP, arachidonic acid). Aggregometry is
recording the signal changes as an aggregation curve which
ranges from 0% (corresponding to platelet rich plasma) to
100% (maximal aggregation corresponding to low platelet
plasma level). The aggregation development is registered over
10 mins maximally and late aggregation is evaluated. Aggre-
gometry examines integrated platelet response to ADP via
P2Y1 and P2Y12 receptors. LTA is an established method for
evaluating high residual platelet reactivity. HPR is defined as
46% of maximal 5 mmol/l ADP-induced aggregation. LTA-
selected HPR correlates well with increased risk of ischemic
vascular events [41]. According to the aggregation agonist used,
it is possible to evaluate either ASA, clopidogrel or gp IIB/IIIA
antagonists. The sensitivity and specificity of LTA for identifying
the risk of ischemic vascular event is up to about 60%.
Substantial is a negative predicitve value of 94% [38]. Even
more demanding than LTA is flow-cytometric examination ofvasodilator stimulated phosphoprotein (VASP). The protein
used in VASP is an intracellular component and the proportion
of its phosphorylation correlates with the level of P2Y12 platelet
blockade. VASP evaluates principally clopidogrel-related high
residual platelet reactivity. A platelet reactivity index over 50%
corresponds to increased residual platelet reactivity [42]. In case
control trials, insufficient P2Y12 platelet blockade by VASP was
found in 60% of patients with subacute in-stent thrombosis
[42,43]. Both methods, LTA and VASP demonstrated quite good
correlation between high on-treatment platelet reactivity and
increased ischemic/thrombotic vascular events. The limitation
of both VASP and LTA is demanding laboratory assessment and
complicated standardization. The advantage of both is high
negative predictive value. The need for fast laboratory evalua-
tion of platelet on-treatment function and complicated evalua-
tion by LTA and VASP initiated the era of point-of-care (POCT)
testing. There is now a broad range of new, more or less POCT
methods but it is necessary to know the advantages/disadvan-
tages and limitations of each, in order to interpret them
properly. Platelet function analyser (PFA-100s) is the only
method for testing comprehensively, primary hemostasis
which is critically dependent on platelet function. The testing
is performed from full citrated blood by drawing it under high
shear stress (5000–6000 s1) through a thin capillary coatedwith
aggregation inductors. The results are expressed as closure
time (CT), which is the time from the beginning of the test to
closure of the capillary. In the case of ASA, responder CT should
exceed 180 s [44], clopidogrel responder CT should exceed 106 s
[45]. In the mechanism of PFA-100, measurement is of both
platelet activation and shear stress which is greater at higher
von Willebrandt factor (vWf) plasma levels. Thus the main
advantage (complex hemostasis evaluation) disappears at
higher levels of vWf. In our sample of 25 patients evaluated
by PFA-100 there were 2 patients with in-stent thrombosis who
were diagnosed as having increased residual platelet reactivity.
One proved to have dual higher on-treatment residual platelet
reactivity. In both cases, we increased the dose of ASA and/or
clopidogrel which led to at least laboratory response. After 6
months, both were free of any clinical cardiovascular events.
In large trials however, neither PFA-100 nor PFA-200 demon-
strated any ability to identify patients at greater risk of ischemic
vascular events [41]. Thus optimal laboratory response to
antiplatelet agents may not be followed by clinical efficacy. In
the opinion of most investigators PFA-100 deemed not suitable
for monitoring antiplatelet blockade, since many factors includ-
ing platelet count, hematocrit, fibrinogen and vWf may influ-
ence the results. Another platelet function assay recently
coming into at least experimental use is Multiple electrode
aggregometry (MEA, Multiplates). In principle this is impe-
dance aggregometry, which can be performed on a full blood
sample. The electrical current passes between two platinum
plates, which are placed in the cuvette with blood sample. The
electrical current causes the electrodes to be covered in plate-
lets. After addition of aggregation agonist both erythrocytes and
leukocytes adhere to the electrodes with platelets and thereby
reduce the electrical current passing through. The change of
signal is registered as aggregation curve, where the area under
the curve is assessed. The area under the curve reflects platelet
activation. To investigate the efficacy of ASA treatment the ASPI
test is, used (aggregation inductor arachidonic acid). To monitor
Table 1 – Pros and cons of platelet function assays.
Method type Vy´hody Nevy´hody
Light transmittance aggregometry ‘‘golden standard’’ Laboratory demanding
Good correlation with CV events Partial dependent on evaluator
VASP Small volume, full blood sample Experienced laboratory personel
gp IIB/IIIA assessment (CD40L, selectin)
PFA-100 POCT, semi-automatic simple von Willebrandova factor dependent
Worse reproducibility
VerifyNOW POCT, semi-automatic, fast, easy Hematokrit dependent
Plateletworks POCT Lack of date linking clinical efficacy
Fast, full blood
Impact-R POCT Lack of date linking clinical efficacy
Full blood
Multielectrode aggregometry Full blood, fast Reagencia preparationþmanual
pipetting
Impedance aggregometry Full blood, good correlation with thrombotic events Time demanding sample preparation
Tromboelastography (platelet
mapping)
Complex information about viscoelastic blood
properties
Lack of trials
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 0 5 – e 3 1 3 e309P2Y12 receptor antagonist the ADP test has to be used (aggrega-
tion inductor—ADP). There is another high sensitivity test called
ADP HS for the P2Y12 receptor antagonist (aggregation inductor/
suppressor ADP, prostaglandin E1). Multiplates is not strictly a
POCT method, since throughout the procedure, qualified use of
the pipette is necessary. MEA is able to identify patients with
HPR and the risk of stent thrombosis with a sensitivity of 100%
and specificity of 86% [46].
The optimal cut-off value for clopidogrel is 4416 AU/min.
This selects patients with a 30-day risk of in-stent thrombosis
with a specificity of 84% and sensitivity of 70% [47]. Moreover,
good correlation between MEA and gold standard (LTA)
results have been demonstrated [48], and even better identi-
fication of patients with stent thrombosis than VASP has
been found [46].
VerifyNOWs is a full POCT method based on turbidimetric
agonist (epinephrine, ADP) induced aggregation examination.
The sample of full citrate containing blood is mixed with
diagnostic agent which consists of human fibrinogen coated
microparticles. The aggregation activation produces aggre-
gates of platelets, erythrocytes and leukocytes with micro-
particles which increases sample transparency. From the
difference in transparency before and after aggregation ago-
nist administration, index units for both ASA and clopidogrel
are calculated. ASA HPR is defined as ARU4550 [49] and
thienopyridine HPR is defined as PRU4236 [41]. In so far the
largest trial, a specificity of 63% and specificity of 60% was
determined for atherothrombotic event prediction by Verify-
NOWs with a negative predictive value of 94% [41].
A less investigated method is the Plateletworkss system
which is based on platelet count difference estimation before
and after aggregation agonist. A specificity of 58% and sensi-
tivity of 63% for atherothrombotic event prediction was found
with a negative predictive value of 94% [41]. The most promis-
ing methods for on-treatment residual platelet activity assess-
ment seem to be Multiplates and VerifyNOWs.3.5. Platelet function assay tailored treatment
The logical consequence of accurate HPR detection by platelet
function assays would be treatment modification. This it is
especially reasonable, if the method has proven good predic-
tion of atherothrombotic events or HPR is confirmed by more
than one test. At our department, there is an ongoing trial,
based on platelet function assays tailored treatment including
LTA, PFA-100/200s, VerifyNOWs and Multiplates (REACT-MI,
see clinicaltrials.gov, NR: NCT01381185). We are trying to assess
patients at greatest risk of atherothrombotic events. Thus only
if 2 methods confirm HPR, we increase the dose of ASA/
clopidogrel or both. The largest conducted trial so far, GRAV-
ITAS, where the dose of clopidogrel (75mg vs 150mg) was
tailored by VerifyNOWs for the following 6 months showed no
benefits of this course [50]. In this trial, there was a low
incidence of primary morbidity/mortality end-point, which
could explain the disappointing results. There is another inter-
esting trial, the ASCET trial aiming to confirm the superiority of
clopidogrel over ASA monotherapy in primary prevention
patients with stable ischemic heart disease and increased HPR
determined by PFA-100. Preliminary results show no lowering of
cardiovascular events in patients randomized to clopidogrel.
The TRIGGER-PCI trial was terminated prematurely due to
insufficient occurrence of primary end-point (Table 2). This
study sought to investigate the efficacy, safety, and antiplate-
let effect of prasugrel as compared with clopidogrel in
patients with high on-treatment platelet reactivity. The clin-
ical utlility of this strategy was not demonstrated due to low
event rate, however, in patients treated with prasugrel there
was increased effectivity of platelet blockade [51]. What are
the results of these trials telling us? The results are mostly
disappointing and do not support the use of platelet function
assays in tailoring antiplatelet treatment. It is necessary to
take into consideration that only residual risk in otherwise
well-treated patients is assessed. The course of further
Table 2 – Platelet function assay driven treatment trials.
Trial Aim Eligibility Pts
number
Treatment strategy Platelet
function
assay
Primary end-point
GRAVITAS HPR tailored
treatment
Elective
PCI, ACS,
DES
n¼2214 Clopidogrel 75 vs 150 mg
for 6 months
VerifyNOWs 6-month CV death, non-
fatal MI or stent
thrombosis
DANTE HPR tailored
treatment
UA/
NSTEMI/
PCI
n¼442 Clopidogrel 75 vs 150 mg
for 6 months
VerifyNOWs 6-month CV death, non-
fatal MI, revascularisation
(CABG/PCI)
ASCET ASA with
Clopidogrel
substitution
tailored by HPR
CHD n¼1001 ASA 160 mg vs Clopidogrel
75 mg
PFA-100s 2-year UA/MI, CVA or
death
TOPAS-1 HPR tailored
stent
thrombosis
abolition
Former
PCIþstent
n¼450 Clopidogrel 600 mg LD,
75 mg/6 months
VerifyNOWs 6-month in-stent
thrombosisVASP
TRIGGER
PCI
HPR tailored
substitution of
clopidogrel
with prasugrel
Elective
PCI
n¼432 Prasugrel 60/10 mg vs
Clopidogrel 600/75 mg
VerifyNOWs CV death, non-fatal MI
ARCTIC HPR tailored
treatment
PCIþDES n¼2500 ASAþClopidogrel dose
increaseþ(dis)continuation
of clopidogrel after 12
months
VerifyNOWs 12-month composite
endpoint: death, MI, CVA,
stent thrombosis, urgent
revascularisation
3T/2R HPR tailored
tirofiban
addition
Elektivnı´
PCI
n¼263 Tirofiban bolus 25 mg/kg/
3 min, 0.1525 mg/kg/14–24 h
VerifyNOWs Periprocedural MI,
30-day death, MI, urgent
revascularisation
PCI—percutaneous coronary intervention, DES—Drug eluting stent, CV—Cardiovascular, CABG—Coronary-aortic by-pass, UA—Unstable
angina pectoris, NSTEMI—Myocardial infarction without ST segment elevation, CVA—cerebrovascular accident, MI—myocardial infarction,
HPR—High platelet reactivity, CHD—Coronary heart disease, —anticipated enrollment number.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 0 5 – e 3 1 3e310development in platelet function assays tailored treatment
will be clear from upcoming trials (Table 2) and their meta-
nalysis. If a method of platelet function assay is available at
your hospital, only patients at higher risk (stent thrombosis,
patients treated with drug eluting stents, diabetics with
multiple ischemic complications) should be examined. This
is however not an official recommendation, rather our per-
sonal point of view. ACC/AHA guidelines for PCI have given a
class IIb recommendation for platelet function testing at high
risk of poor clinical outcome [52], ESC guidelines are recom-
mending platelet function testing (class IIb) only if it may
alter further management [53]. If we determine HPR for ASA
and/or clopidogrel we may either increase the dose or change
the agent. After increasing the dose of ASA, we should re-
examine the HPR (laboratory) after several hours. In the case
of clopidogrel the testing is reasonable in the following 3–5
days. Another option is to substitute clopidogrel with prasu-
grel (Efients). In the key TRITON TIMI 38 trial prasugrel
demonstrated reduced ischemic vascular events in compar-
ison with clopidogrel. However there was no impact on
cardiovascular or all-cause mortality and on the other
increased risk of fatal bleeding [54]. A smaller RESPOND trial
proved at least the laboratory efficacy of ticagrelor for
clopidogrel substitution which points to a future promising
solution [55]. There is lack of evidence to substitute either
prasugrel or ticagrelor for clopidogrel only based on HPR
assessment. The on-going ARCTIC trial will provide us with
more insights about platelet function tailored treatment withprasugrel in patients with HPR on clopidogrel after elective
PCI with drug eluting stent [56,57]. Ticagrelor is not a prodrug,
which is its biggest advantage over clopidogrel and prasugrel.
From the PLATO trial, we know that ticagrelor is able to
reduce ischemic vascular events in comparison with clopido-
grel with mild increase in bleeding events [58]. Another
option for tailoring antiplatelet treatment is genetic testing.
According to Dr. Mega’s ELEVATE TIMI 56 the substitution of
clopidogrel for either prasugrel or ticagrelor is indicated only
in CYP2C192 homozygotes [29]. In most of the trials platelet
function testing was performed before or early after PCI.
However, periprocedural platelet function assessment is
inferior to platelet monitoring in different time points, what
may potentially limit the benefit of platelet function tailored
treatment [59].
Platelet function assays is a matter of intensive research.
There is so far lack of evidence for initiating routine exam-
ination, however. Thus treatment modification should not be
led only by HPR but foremost by clinical events using HPR as
additive information especially in high risk patients.4. Conclusion
Platelet function assays are, from a laboratory point of view
established but from a clinical perspective we are still at the
beginning.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 0 5 – e 3 1 3 e311The key knowledge on HPR/platelet function assays is as
follows:1. The terms aspirin/clopidogrel resistance are vague. We
should substitute them by more accurate high on-treatment
residual platelet reactivity (HPR).2. There is a broad spectrum of platelet function assay. The
clinician needs to be acquainted with each, to know what
they are testing and to properly interpret them, excluding
extraneous factors.3. Platelet function assays are demonstrating ‘‘laboratory’’
HPR, for our patients is foremost important if it is followed
by increased occurrence of ischemic vascular events4. Platelet function assays are more or less aiming to assess
primary hemostasis or indirectly the level of platelet activa-
tion, which is however not the only cause of atherothrom-
bosis. Still there are classical risk factors (diabetes mellitus,
renal insufficiency, smoking etc. [60]) and procedural risks
(stent length/diameter, bifurcational stent, the number and
character of stenosis etc.) which play important roles.
Our requirements for platelet function assay should be:1. Clearly demonstrated correlation between test abnormal-
ity and ischemic vascular risk2. Interlaboratory standardization3. Assay-based treatment tailoring4. Appropriate cost/benefit ratio5. Easy to examine—POCT6. Reproducible
In some aspects the requirements sound a bit ‘‘sci-fi’’, butcurrently there are already some methods fulfilling this criteria.
According to the available evidence, the most appropriate
methods are Multiplates and VerifyNOWs. Platelet function
examination is not a routine method in cardiology so far. It is
necessary to be very careful with platelet function interpretation.
In the decision-making process it should only add new informa-
tion and not completely change the approach. We believe that
after completion of interventional trials, platelet function assays
will help to tailor reasonably the antiplatelet treatment.
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